Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
March 11, 2024 08:30 ET
|
Dyadic International, Inc.
JUNIPER, Fla., March 11, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
February 21, 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced...
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
February 06, 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a...
Dyadic Attends Investor Events in December
November 30, 2023 08:30 ET
|
Dyadic International, Inc.
Dyadic Attends Investor Events in December
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
November 29, 2023 08:30 ET
|
Dyadic International, Inc.
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 08, 2023 16:00 ET
|
Dyadic International, Inc.
Received an upfront payment of $0.6 million in October for product development and licensing of our Dapibus™ platform for animal-free dairy enzyme productsDYAI-100 Phase 1 clinical trial top-line...
Plant-based Vaccines Market Size to Hit 12.9% CAGR, Globally, by 2028 - Exclusive Report by The Insight Partners
November 01, 2023 06:59 ET
|
The Insight Partners
Pune, India, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Plants are an important source to produce cost-effective vaccine derivatives. Plant-based vaccines can be made in a cost-effective way and produced on...
Pfizer und BioNTech geben erste positive Daten für mRNA-basiertes Kombinationsimpfstoffprogramm gegen Influenza und COVID-19 bekannt
October 26, 2023 06:45 ET
|
BioNTech SE
Die in der Phase-1/2-Studie untersuchten führenden Kombi-Impfstoffformulierungen zeigten robuste Immunantworten gegen Influenza A, Influenza B und SARS-CoV-2-Stämme Das Sicherheitsprofil der...
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
October 26, 2023 06:45 ET
|
BioNTech SE
Lead formulations evaluated in the Phase 1/2 study demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains Safety profile of the mRNA-based combination vaccine...
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
October 25, 2023 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...